cryptococcosis – mycolab.ai

The emerging fungal pathogen Cryptococcus gattii: Epidemiology, pathogenesis, immunomodulatory attributes, and drug susceptibility

mycolabadmin

Cryptococcus gattii is a dangerous fungal infection that can affect even healthy people, unlike most fungal infections that target those with weak immune systems. The fungus uses clever tricks to hide from the immune system, including creating protective capsules and producing melanin. Current antifungal drugs like fluconazole are becoming less effective as the fungus develops resistance, making this an urgent public health concern that requires better treatments and early detection.

What Do We Know About Cryptococcus spp. in Portugal? One Health Systematic Review in a Comprehensive 13-Year Retrospective Study (2013–2025)

mycolabadmin

This study examines cryptococcosis, a fungal infection that affects both animals and humans, across Portugal from 2013-2025. Researchers found that about 4.5% of animal samples tested positive for Cryptococcus species, with infections most common in dogs and cats. The infections peaked during summer months and were most prevalent in central Portugal, with different fungal species affecting different animal types. The research emphasizes the importance of coordinated monitoring across animals, humans, and the environment to better understand and control this disease.

Spatial distribution of pathogenic fungal isolates from clinical samples in Uganda: Diagnostic gaps and trends, January 2020 – May 2024

mycolabadmin

This study examined fungal infections detected in Uganda’s laboratories from 2020 to 2024, finding that common yeast infections called Candida were the most frequently identified. Most cases occurred in women aged 16-35 years, particularly in the cities of Kampala and Mbarara. The research reveals that Uganda’s laboratories can only identify two types of fungi and cannot test which medications work best against them, highlighting the need for better diagnostic tools and training.

Emerging Infections Network Survey of Screening for Cryptococcal Antigenemia, United States, 2024

mycolabadmin

This survey asked infectious disease doctors across the United States about their use of a simple blood test (cryptococcal antigen screening) for HIV patients. The test can detect a dangerous fungal infection weeks before symptoms appear, allowing for early treatment. However, the survey found that many doctors are not using this recommended test regularly, primarily because they are unsure about its benefits and are confused about screening guidelines.

Clinical spectrum, immune status, and prognostic factors of cryptococcosis: insights from a large, multi-center, ambispective cohort study in southeastern China

mycolabadmin

This study examined cryptococcosis, a serious fungal infection, in 396 non-HIV patients across hospitals in southeastern China. The researchers found that patients’ immune status, whether the infection spread to the brain, and blood inflammation markers were key predictors of survival. Most patients treated with azole medications (a common antifungal) improved or recovered, though those with brain involvement or severe immune deficiency had worse outcomes. The findings help doctors identify which patients need more intensive treatment.

Is Cryptococcus neoformans a pleomorphic fungus?

mycolabadmin

Cryptococcus neoformans is a dangerous fungal pathogen that causes serious infections in humans. For many years, scientists thought this fungus existed primarily as regular yeast cells. However, new research shows the fungus can change into several different cell forms during infection, including larger ‘titan cells’ and smaller ‘seed cells.’ These shape-shifting abilities help the fungus survive in the human body and evade immune responses, making infections harder to treat.

Conjugation of a Cryptococcus neoformans-derived metalloprotease to antifungal-loaded PLGA nanoparticles treats neural cryptococcosis in an in vitro model

mycolabadmin

Researchers developed special nanoparticles that can cross the protective barrier surrounding the brain by using a protein from a fungal infection. These nanoparticles are loaded with an antifungal drug and can effectively treat cryptococcal brain infections in laboratory tests. This approach offers a new way to deliver medicines to the brain without invasive procedures, potentially helping patients with serious brain infections that are currently difficult to treat.

Primary cutaneous mixed infection with Cryptococcus uniguttulatus and Mycobacterium tuberculosis

mycolabadmin

A 43-year-old man had a persistent facial rash that didn’t improve with standard antifungal treatments. Doctors initially found a fungal infection called Cryptococcus uniguttulatus using culture tests. However, advanced molecular testing (DNA sequencing) revealed he also had a tuberculosis infection in the same skin lesion. Once both infections were treated with appropriate medications, the patient’s rash finally improved. This case shows that sometimes people can have multiple infections at the same location and that newer diagnostic methods are important for finding these hidden infections.

Cryptococcal endophthalmitis in a patient with malignancy: A case report and literature review

mycolabadmin

A 50-year-old woman with advanced lung cancer developed a rare fungal eye infection caused by Cryptococcus neoformans, resulting in blurred vision. Doctors diagnosed this through eye surgery and fluid analysis, then treated her with strong antifungal medications both injected into the eye and given systemically. After 10 months of treatment, her vision significantly improved, showing that early detection and aggressive antifungal therapy are critical for preventing blindness from this rare infection.

Research Topic: cryptococcosis